Theranostic Applications of Scaffolds in Current Biomedical Research DOI Open Access

Sarika J Patil,

Vandana M Thorat, Akshada Amit Koparde

et al.

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 17, 2024

Theranostics, a remarkable combination of diagnostics and therapeutics, has given rise to tissue/organ-format theranostic scaffolds that integrate targeted therapy real-time disease monitoring. The scaffold is 3D structuring template for cell or tissue attachment growth. These offer unprecedented opportunities personalized medicine hold great potential revolutionizing healthcare. Recent advancements in fabrication techniques have enabled the creation highly intricate precisely engineered with controllable physical chemical properties, enhancing their therapeutic engineering regenerative medicine. This paper proposes new categorization method based on relativity design-independent parameters. Five types are defined at different levels, highlighting importance understanding analyzing types. It possesses ability seamlessly therapeutics within single platform, efficacy precision Natural derived from biomaterials synthetic fabricated by human intervention discussed, offering advantages such as tunable mechanical properties controlled drug delivery, while natural provide inherent biocompatibility bioactivity, making them ideal promoting cellular responses. use shows promise advancing improving patient outcomes. transfer technologies changes society accelerated evolution health monitoring into era personal Using emerging data, cost-effective analytics, wireless sensor networks, mobile smartphones, easy internet access, these expected accelerate transition outside traditional healthcare settings. main objective this review article comprehensive overview applications current biomedical research, dual role diagnostics. aims explore latest design, fabrication, functionalization, emphasizing how innovations contribute improved efficacy, progression across various medical fields.

Language: Английский

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up DOI Creative Commons
Lizza Hendriks,

Keith M. Kerr,

Jessica Menis

et al.

Annals of Oncology, Journal Year: 2023, Volume and Issue: 34(4), P. 339 - 357

Published: Jan. 23, 2023

Language: Английский

Citations

439
Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer DOI Creative Commons
Ellen Heitzer, Daan van den Broek, Marc G. Denis

et al.

ESMO Open, Journal Year: 2022, Volume and Issue: 7(2), P. 100399 - 100399

Published: Feb. 21, 2022

Liquid biopsy (LB) is a rapidly evolving diagnostic tool for precision oncology that has recently found its way into routine practice as an adjunct to tissue (TB). The concept of LB refers any tumor-derived material, such circulating tumor DNA (ctDNA) or cells are detectable in blood. An not limited the blood and may include other fluids cerebrospinal fluid, pleural effusion, urine, among others.

Language: Английский

Citations

80
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial DOI Creative Commons
Benjamin Besse, Elvire Pons‐Tostivint, Keunchil Park

et al.

Nature Medicine, Journal Year: 2024, Volume and Issue: 30(3), P. 716 - 729

Published: Feb. 13, 2024

Abstract For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable molecular alterations, standard-of-care treatment is immunotherapy anti-PD-(L)1 checkpoint inhibitors, alone or platinum-doublet therapy. However, not all derive durable benefit and resistance to immune blockade common. Understanding mechanisms of resistance—which can include defects in DNA damage response repair pathways, alterations functional mutations STK11 /LKB1, antigen-presentation immunosuppressive cellular subsets within the tumor microenvironment—and developing effective therapies overcome them, remains an unmet need. Here phase 2 umbrella HUDSON study evaluated rational combination regimens for advanced NSCLC following failure anti-PD-(L)1-containing A total 268 received durvalumab (anti-PD-L1 monoclonal antibody)–ceralasertib (ATR kinase inhibitor), durvalumab–olaparib (PARP durvalumab–danvatirsen (STAT3 antisense oligonucleotide) durvalumab–oleclumab (anti-CD73 antibody). Greatest clinical was observed durvalumab–ceralasertib; objective rate (primary outcome) 13.9% (11/79) versus 2.6% (5/189) other regimens, pooled, median progression-free survival (secondary 5.8 (80% confidence interval 4.6–7.4) 2.7 (1.8–2.8) months, overall 17.4 (14.1–20.3) 9.4 (7.5–10.6) months. Benefit durvalumab–ceralasertib consistent across known immunotherapy-refractory subgroups. In ATM -altered hypothesized harbor vulnerability ATR inhibition, 26.1% (6/23) survival/median were 8.4/22.8 Durvalumab–ceralasertib safety/tolerability profile manageable. Biomarker analyses suggested that anti-PD-L1/ATR inhibition induced changes reinvigorated antitumor immunity. under further investigation NSCLC. ClinicalTrials.gov identifier: NCT03334617

Language: Английский

Citations

30
Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries DOI Creative Commons
Vincent D. de Jager, Wim Timens,

Arnaud Bayle

et al.

The Lancet Regional Health - Europe, Journal Year: 2024, Volume and Issue: 38, P. 100838 - 100838

Published: March 1, 2024

In the past two decades, treatment of metastatic non-small cell lung cancer (NSCLC), has undergone significant changes due to introduction targeted therapies and immunotherapy. These advancements have led need for predictive molecular tests identify patients eligible therapy. This review provides an overview development current application biomarker testing in European with advanced stage NSCLC. Using data from eleven countries, we conclude that recommendations are incorporated national guidelines across Europe, although there differences their comprehensiveness. Moreover, availability recently EMA-approved varies between countries. Unfortunately, routine assessment national/regional rates is limited. As a result, it remains uncertain which proportion NSCLC Europe receive adequate testing. Lastly, Molecular Tumor Boards (MTBs) discussion test results widely implemented, but composition functioning lacking. The establishment MTB can provide framework interpreting rare or complex mutations, facilitating appropriate decision-making, ensuring quality control.

Language: Английский

Citations

26
The evolving role of liquid biopsy in lung cancer DOI
Umberto Malapelle, Pasquale Pisapia, Francesco Pepe

et al.

Lung Cancer, Journal Year: 2022, Volume and Issue: 172, P. 53 - 64

Published: Aug. 10, 2022

Language: Английский

Citations

48
Tackling Osimertinib Resistance in EGFR-Mutant Non–Small Cell Lung Cancer DOI
Juan Bautista Blaquier, Sandra Ortiz-Cuarán, Biagio Ricciuti

et al.

Clinical Cancer Research, Journal Year: 2023, Volume and Issue: 29(18), P. 3579 - 3591

Published: April 24, 2023

The current landscape of targeted therapies directed against oncogenic driver alterations in non-small cell lung cancer (NSCLC) is expanding. Patients with EGFR-mutant NSCLC can derive significant benefit from EGFR tyrosine kinase inhibitor (TKI) therapy, including the third-generation TKI osimertinib. However, invariably, all patients will experience disease progression this therapy mainly due to adaptation cells through primary or secondary molecular mechanisms resistance. comprehension and access tissue cell-free DNA next-generation sequencing have fueled development innovative therapeutic strategies prevent overcome resistance osimertinib clinical setting. Herein, we review biological implications ongoing

Language: Английский

Citations

37
Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation DOI Creative Commons
John R. Gosney, Luís Paz-Ares, Pasi A. Jänne

et al.

ESMO Open, Journal Year: 2023, Volume and Issue: 8(4), P. 101587 - 101587

Published: June 25, 2023

Biomarker tests in lung cancer have been traditionally ordered by the treating oncologist upon confirmation of an appropriate pathological diagnosis. The delay this introduces prolongs yet further what is already a complex, multi-stage, pre-treatment pathway and delays start first-line systemic treatment, which crucially informed results such analysis. Reflex testing, responsibility for testing agreed range biomarkers lies with pathologist, has shown to standardise expedite process. Twelve experts discussed rationale considerations implementing reflex as standard clinical practice.

Language: Английский

Citations

26
RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape DOI Creative Commons
Silvia Novello, Raffaele Califano, Niels Reinmuth

et al.

The Oncologist, Journal Year: 2023, Volume and Issue: 28(5), P. 402 - 413

Published: Feb. 23, 2023

Abstract The objective of this narrative review is to summarize the efficacy and safety available therapies for rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), including in patients with central nervous system (CNS) metastases. Background information provided on RET rearrangements NSCLC molecular testing options as well an overview clinical guidelines testing, which recommend broad rearrangements. potential treatments NSCLC, multikinase inhibitors, RET-selective pemetrexed-based therapy, immunotherapies are reviewed from Phase I/II `real-world’ studies, alongside primary secondary resistance mechanisms. selpercatinib pralsetinib, preferred first-line therapy metastatic recommended subsequent if inhibitors have not been used setting.

Language: Английский

Citations

25
Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology DOI Creative Commons
Juan Carlos Laguna, Miguel García-Pardo, Joao V. Alessi

et al.

Therapeutic Advances in Medical Oncology, Journal Year: 2024, Volume and Issue: 16

Published: Jan. 1, 2024

Lung cancer poses a global health challenge and stands as the leading cause of cancer-related deaths worldwide. However, its incidence, mortality, characteristics are not uniform across all regions Understanding factors contributing to this diversity is crucial in prevalent disease where most cases diagnosed advanced stages. Hence, prevention early diagnosis emerge efficient strategies enhance outcomes. In Western societies, tobacco consumption constitutes primary risk factor for lung cancer, accounting up 90% cases. other geographic locations, different significant play fundamental role development, such individual genetic predisposition, or exposure carcinogens radon gas, environmental pollution, occupational exposures, specific infectious diseases. Comprehensive clinical molecular characterization recent decades has enabled us distinguish subtypes with distinct phenotypes, genotypes, immunogenicity, treatment responses, survival rates. The ultimate goal prevent individualize management each community improve patient

Language: Английский

Citations

14
Assessing the Cost-Effectiveness of Next-Generation Sequencing as a Biomarker Testing Approach in Oncology and Policy Implications: A Literature Review DOI

Myriam Mirza,

Lutz Goerke, Anna Anderson

et al.

Value in Health, Journal Year: 2024, Volume and Issue: 27(9), P. 1300 - 1309

Published: May 8, 2024

Language: Английский

Citations

11